Amicus Therapeutics, Inc. (LON: 0HF9)
London
· Delayed Price · Currency is GBP · Price in USD
9.54
+0.02 (0.21%)
Jan 22, 2025, 3:30 PM BST
Amicus Therapeutics Revenue
Amicus Therapeutics had revenue of $141.52M USD in the quarter ending September 30, 2024, with 36.73% growth. This brings the company's revenue in the last twelve months to $493.67M, up 32.58% year-over-year. In the year 2023, Amicus Therapeutics had annual revenue of $399.36M with 21.30% growth.
Revenue (ttm)
$493.67M
Revenue Growth
+32.58%
P/S Ratio
n/a
Revenue / Employee
$954.88K
Employees
517
Market Cap
2.31B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 399.36M | 70.12M | 21.30% |
Dec 31, 2022 | 329.23M | 23.72M | 7.76% |
Dec 31, 2021 | 305.51M | 44.63M | 17.11% |
Dec 31, 2020 | 260.89M | 78.65M | 43.16% |
Dec 31, 2019 | 182.24M | 90.99M | 99.72% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 38.20B |
GSK plc | 31.31B |
Haleon | 11.24B |
Smith & Nephew | 4.46B |
ConvaTec Group | 1.74B |
Hikma Pharmaceuticals | 2.39B |
HUTCHMED (China) | 483.31M |
Oxford Nanopore Technologies | 167.75M |
Amicus Therapeutics News
- 9 days ago - NCLA Amicus Brief Asks Supreme Court to Keep Unlawful Corporate Transparency Act Enjoined - GlobeNewsWire
- 9 days ago - 3 Oversold Biotech Names - Seeking Alpha
- 10 days ago - Amicus Therapeutics expects 2024 revenue slightly above consensus, guides 2025 - Seeking Alpha
- 10 days ago - Amicus Therapeutics Inc (FOLD) Reports Strong 2024 Revenue Growth and Positive Outlook for 2025 - GuruFocus
- 10 days ago - Amicus Therapeutics Reports Preliminary 2024 Revenue and Provides 2025 Strategic Outlook - GlobeNewsWire
- 21 days ago - Amicus Therapeutics Inc (FOLD) to Present at J.P. Morgan Healthcare Conference - GuruFocus
- 21 days ago - Amicus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 24 days ago - Fold, Inc. Announces Up To $30 Million Convertible Note Financing Backed by Bitcoin - Business Wire